Patent · US Active

Substituted oxopyridine derivative

US11884660B2 · kind B2 · utility

0Cited by

12References

7Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Mario Lobell · Wuppertal, DE
Hartmut Schirok · Wuppertal, DE
Adrian Tersteegen · Wuppertal, DE

Key dates

Filing date	Apr 3, 2019
Grant date	Jan 30, 2024
Priority date	—
Expiry date	May 4, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P7/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.